Elvire Pons‐Tostivint
Nantes Université(FR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial(2023)264 cited
- → Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck(2019)180 cited
- → Molecular biomarkers for lung adenocarcinoma(2017)167 cited
- → Targeting PI3K Signaling in Combination Cancer Therapy(2017)145 cited
- → Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study(2024)144 cited
- → Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases(2016)118 cited
- → Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial(2024)108 cited
- → Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials(2019)96 cited
- → STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact(2021)95 cited
- → Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study(2025)74 cited